Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Mirati Therapeutics, Inc. MRTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
55/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$102.10
+73.9%

Mirati Therapeutics, Inc. (MRTX) is a Biotechnology company in the Healthcare sector, currently trading at $58.70. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is MRTX = $102 (+73.9% upside).

Financials: revenue is $12M, +219%/yr average growth. Net income is $741M (loss), growing at -52.6%/yr. Net profit margin is -5957.4% (negative). Gross margin is 95.2% (+5478.4 pp trend).

Balance sheet: total debt is $52M against $997M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 6.96 (strong liquidity). Debt-to-assets is 4.3%. Total assets: $1.2B.

Analyst outlook: 14 / 31 analysts rate MRTX as buy (45%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).

$102.10
▲ 73.94% Upside
Average Price Target
Based on 31 Wall Street analysts offering 12-month price targets for Mirati Therapeutics, Inc., the average price target is $102.10, with a high forecast of $247.00, and a low forecast of $53.00.
Highest Price Target
$247.00
Average Price Target
$102.10
Lowest Price Target
$53.00

MRTX SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MRTX

✓
VALUE Pass
100/100
MRTX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $102, implying +73.8% from the current price $59. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
MRTX: +219%/yr revenue is, -52.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet MRTX: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 6.96 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
MRTX: Gross margin is 95.2% (+5478.4 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 14 / 31 analysts rate MRTX as buy (45%). Analyst consensus target is $102 (+73.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
MRTX: Net profit margin is -5957.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range27.3-64.41
Volume20.96M
Avg Volume (30D)1.78M
Market Cap$4.12B
Beta (1Y)0.77
Share Statistics
EPS (TTM)-13.18
Shares Outstanding$56.23M
IPO Date2013-07-15
Employees587
CEOCharles M. Baum
Financial Highlights & Ratios
Revenue (TTM)$12.44M
Gross Profit$11.84M
EBITDA$-756.66M
Net Income$-740.87M
Operating Income$-759.59M
Total Cash$1.08B
Total Debt$51.51M
Net Debt$-183.76M
Total Assets$1.2B
Price / Earnings (P/E)-4.5
Price / Sales (P/S)331.11
Analyst Forecast
1Y Price Target$66.50
Target High$247.00
Target Low$53.00
Upside+13.3%
Rating ConsensusHold
Analysts Covering31
Buy 45% Hold 55% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS60468T1051

Price Chart

Track all markets on TradingView
MRTX
Mirati Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
27.30 52WK RANGE 64.41

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 PTCT
PTCT
PTC Therapeutics, Inc.
$73.01
+3.68%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.52
+1.46%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message